{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:08:10Z","timestamp":1790125690738,"version":"4.0.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Pfizer (Thailand) Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-025-02074-4","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T13:33:06Z","timestamp":1748871186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Expert consensus on gepants for acute and preventive treatment of migraine in Thailand"],"prefix":"10.1186","volume":"26","author":[{"given":"Prakit","family":"Anukoolwittaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanakorn","family":"Rattanawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiratikorn","family":"Vongvaivanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanakit","family":"Pongpitakmetha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sekh","family":"Thanprasertsuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaninjitra","family":"Poonpedpun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pannathat","family":"Soontrapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanokrat","family":"Suwanlaong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kannikar","family":"Kongbunkiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surasak","family":"Komonchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petcharat","family":"Dusitanond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chutithep","family":"Teekaput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nopdanai","family":"Sirimaharaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadolporn","family":"Yuvasilp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surat","family":"Tanprawate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"issue":"6","key":"2074_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 14(6):338\u2013350. https:\/\/doi.org\/10.1038\/s41582-018-0003-1","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"2074_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11916-023-01142-1","volume":"27","author":"D Li","year":"2023","unstructured":"Li D, Abreu J, Tepper SJ (2023) A brief review of gepants. Curr Pain Headache Rep 27(9):479\u2013488. https:\/\/doi.org\/10.1007\/s11916-023-01142-1","journal-title":"Curr Pain Headache Rep"},{"issue":"8","key":"2074_CR3","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1080\/14656566.2023.2201375","volume":"24","author":"J Tajti","year":"2023","unstructured":"Tajti J, Szok D, Csati A, Vecsei L (2023) The pharmacotherapeutic management of episodic and chronic migraine with gepants. Expert Opin Pharmacother 24(8):947\u2013958. https:\/\/doi.org\/10.1080\/14656566.2023.2201375","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"2074_CR4","doi-asserted-by":"publisher","first-page":"333102424125266","DOI":"10.1177\/03331024241252666","volume":"44","author":"F Puledda","year":"2024","unstructured":"Puledda F, Sacco S, Diener HC, Ashina M, Al-Khazali HM, Ashina S et al (2024) International headache society global practice recommendations for the acute Pharmacological treatment of migraine. Cephalalgia 44(8):3331024241252666. https:\/\/doi.org\/10.1177\/03331024241252666","journal-title":"Cephalalgia"},{"issue":"4","key":"2074_CR5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A, Headache A, S (2024) Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American headache society position statement update. Headache 64(4):333\u2013341. https:\/\/doi.org\/10.1111\/head.14692","journal-title":"Headache"},{"issue":"9","key":"2074_CR6","doi-asserted-by":"publisher","first-page":"333102424126973","DOI":"10.1177\/03331024241269735","volume":"44","author":"F Puledda","year":"2024","unstructured":"Puledda F, Sacco S, Diener HC, Ashina M, Al-Khazali HM, Ashina S et al (2024) International headache society global practice recommendations for preventive Pharmacological treatment of migraine. Cephalalgia 44(9):3331024241269735. https:\/\/doi.org\/10.1177\/03331024241269735","journal-title":"Cephalalgia"},{"key":"2074_CR7","unstructured":"Thai Headache Society (2022) The Neurological Society of Thailand. Clinical Practice Guidelines on Diagnosis and Treatment of Migraine"},{"key":"2074_CR8","doi-asserted-by":"publisher","unstructured":"Dalkey N, Helmer O (1963) An experimental application of the Delphi method to the use of experts. Manage Sci 9(3):458\u2013467. https:\/\/doi.org\/10.1287\/mnsc.9.3.458","DOI":"10.1287\/mnsc.9.3.458"},{"key":"2074_CR9","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition (2018) Cephalalgia, 38(1), 1-211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"issue":"4","key":"2074_CR10","doi-asserted-by":"publisher","first-page":"333102424124565","DOI":"10.1177\/03331024241245658","volume":"44","author":"W Rattanawong","year":"2024","unstructured":"Rattanawong W, Rapoport A, Srikiatkhachorn A (2024) Medication underuse headache. Cephalalgia 44(4):3331024241245658. https:\/\/doi.org\/10.1177\/03331024241245658","journal-title":"Cephalalgia"},{"key":"2074_CR11","doi-asserted-by":"publisher","first-page":"100094","DOI":"10.1016\/j.ynpai.2022.100094","volume":"12","author":"W Rattanawong","year":"2022","unstructured":"Rattanawong W, Rapoport A, Srikiatkhachorn A (2022) Neurobiology of migraine progression. Neurobiol Pain 12:100094. https:\/\/doi.org\/10.1016\/j.ynpai.2022.100094","journal-title":"Neurobiol Pain"},{"issue":"2","key":"2074_CR12","doi-asserted-by":"publisher","first-page":"333102425132060","DOI":"10.1177\/03331024251320608","volume":"45","author":"S Sacco","year":"2025","unstructured":"Sacco S, Ashina M, Diener HC, Haghdoost F, Lee MJ, Monteith TS et al (2025) Setting higher standards for migraine prevention: A position statement of the international headache society. Cephalalgia 45(2):3331024251320608. https:\/\/doi.org\/10.1177\/03331024251320608","journal-title":"Cephalalgia"},{"issue":"1","key":"2074_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12325-023-02650-7","volume":"41","author":"E Bentivegna","year":"2024","unstructured":"Bentivegna E, Galastri S, Onan D, Martelletti P (2024) Unmet needs in the acute treatment of migraine. Adv Ther 41(1):1\u201313. https:\/\/doi.org\/10.1007\/s12325-023-02650-7","journal-title":"Adv Ther"},{"key":"2074_CR14","doi-asserted-by":"publisher","first-page":"114147","DOI":"10.1016\/j.bcp.2020.114147","volume":"180","author":"S Bindu","year":"2020","unstructured":"Bindu S, Mazumder S, Bandyopadhyay U (2020) Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol 180:114147. https:\/\/doi.org\/10.1016\/j.bcp.2020.114147","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"2074_CR15","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s13311-017-0592-1","volume":"15","author":"JJY Ong","year":"2018","unstructured":"Ong JJY, De Felice M (2018) Migraine treatment: current acute medications and their potential. Mech Action Neurother 15(2):274\u2013290. https:\/\/doi.org\/10.1007\/s13311-017-0592-1","journal-title":"Mech Action Neurother"},{"issue":"4","key":"2074_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11910-016-0634-9","volume":"16","author":"RE Wells","year":"2016","unstructured":"Wells RE, Turner DP, Lee M, Bishop L, Strauss L (2016) Managing migraine during pregnancy and lactation. Curr Neurol Neurosci Rep 16(4):40. https:\/\/doi.org\/10.1007\/s11910-016-0634-9","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"2074_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s10194-022-01502-z","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Lampl C, Amin FM, Braschinsky M, Deligianni C, Uluduz D et al (2022) European headache federation (EHF) consensus on the definition of effective treatment of a migraine attack and of Triptan failure. J Headache Pain 23(1):133. https:\/\/doi.org\/10.1186\/s10194-022-01502-z","journal-title":"J Headache Pain"},{"issue":"1","key":"2074_CR18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s10194-024-01904-1","volume":"25","author":"W Laohapiboolrattana","year":"2024","unstructured":"Laohapiboolrattana W, Jansem P, Anukoolwittaya P, Roongpiboonsopit D, Hiransuthikul A, Pongpitakmetha T et al (2024) Efficacy of Lasmiditan, Rimegepant and ubrogepant for acute treatment of migraine in Triptan insufficient responders: systematic review and network meta-analysis. J Headache Pain 25(1):194. https:\/\/doi.org\/10.1186\/s10194-024-01904-1","journal-title":"J Headache Pain"},{"issue":"2","key":"2074_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40120-023-00438-z","volume":"12","author":"E Bentivegna","year":"2023","unstructured":"Bentivegna E, Onan D, Martelletti P (2023) Unmet needs in preventive treatment of migraine. Neurol Ther 12(2):337\u2013342. https:\/\/doi.org\/10.1007\/s40120-023-00438-z","journal-title":"Neurol Ther"},{"issue":"7","key":"2074_CR20","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS, Board of Directors of the American Headache (2021) The American headache society consensus statement: update on integrating new migraine treatments into clinical practice. Headache 61(7):1021\u20131039. https:\/\/doi.org\/10.1111\/head.14153","journal-title":"Headache"},{"issue":"23","key":"2074_CR21","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","volume":"381","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM et al (2019) Ubrogepant for the treatment of migraine. N Engl J Med 381(23):2230\u20132241. https:\/\/doi.org\/10.1056\/NEJMoa1813049","journal-title":"N Engl J Med"},{"issue":"19","key":"2074_CR22","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.2019.16711","volume":"322","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A et al (2019) Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA 322(19):1887\u20131898. https:\/\/doi.org\/10.1001\/jama.2019.16711","journal-title":"JAMA"},{"issue":"2","key":"2074_CR23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M et al (2019) Rimegepant, an oral calcitonin Gene-Related peptide receptor antagonist, for migraine. N Engl J Med 381(2):142\u2013149. https:\/\/doi.org\/10.1056\/NEJMoa1811090","journal-title":"N Engl J Med"},{"issue":"10200","key":"2074_CR24","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG et al (2019) Efficacy, safety, and tolerability of Rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 394(10200):737\u2013745. https:\/\/doi.org\/10.1016\/S0140-6736(19)31606-X","journal-title":"Lancet"},{"issue":"3","key":"2074_CR25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1474-4422(22)00517-8","volume":"22","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Croop R, Stock DA, Madonia J, Forshaw M, Lovegren M et al (2023) Safety, tolerability, and efficacy of Zavegepant 10\u00a0mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol 22(3):209\u2013217. https:\/\/doi.org\/10.1016\/S1474-4422(22)00517-8","journal-title":"Lancet Neurol"},{"issue":"2","key":"2074_CR26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40120-024-00586-w","volume":"13","author":"T Alsaadi","year":"2024","unstructured":"Alsaadi T, Suliman R, Santos V, Al Qaisi I, Carmina P, Aldaher B et al (2024) Safety and tolerability of combining CGRP monoclonal antibodies with gepants in patients with migraine: A retrospective study. Neurol Ther 13(2):465\u2013473. https:\/\/doi.org\/10.1007\/s40120-024-00586-w","journal-title":"Neurol Ther"},{"key":"2074_CR27","doi-asserted-by":"publisher","first-page":"1130239","DOI":"10.3389\/fpain.2023.1130239","volume":"4","author":"T Shah","year":"2023","unstructured":"Shah T, Bedrin K, Tinsley A (2023) Calcitonin gene relating peptide inhibitors in combination for migraine treatment: A mini-review. Front Pain Res (Lausanne) 4:1130239. https:\/\/doi.org\/10.3389\/fpain.2023.1130239","journal-title":"Front Pain Res (Lausanne)"},{"issue":"8","key":"2074_CR28","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1093\/brain\/awae062","volume":"147","author":"A Melo-Carrillo","year":"2024","unstructured":"Melo-Carrillo A, Strassman AM, Broide R, Adams A, Dabruzzo B, Brin M et al (2024) Novel insight into Atogepant mechanisms of action in migraine prevention. Brain 147(8):2884\u20132896. https:\/\/doi.org\/10.1093\/brain\/awae062","journal-title":"Brain"},{"key":"2074_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/head.14871","author":"J Ailani","year":"2024","unstructured":"Ailani J, Lipton RB, Blumenfeld AM, Mechtler L, Klein BC, He MY et al (2024) Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking Atogepant for the preventive treatment of episodic migraine: results from the TANDEM study. Headache. https:\/\/doi.org\/10.1111\/head.14871","journal-title":"Headache"},{"issue":"4","key":"2074_CR30","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.nrl.2017.09.014","volume":"36","author":"AB Gago-Veiga","year":"2021","unstructured":"Gago-Veiga AB, Vivancos J, Sobrado M (2021) The premonitory phase: A crucial stage in migraine. Neurologia (Engl Ed) 36(4):298\u2013304. https:\/\/doi.org\/10.1016\/j.nrl.2017.09.014","journal-title":"Neurologia (Engl Ed)"},{"issue":"10419","key":"2074_CR31","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/S0140-6736(23)01683-5","volume":"402","author":"DW Dodick","year":"2023","unstructured":"Dodick DW, Goadsby PJ, Schwedt TJ, Lipton RB, Liu C, Lu K et al (2023) Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. Lancet 402(10419):2307\u20132316. https:\/\/doi.org\/10.1016\/S0140-6736(23)01683-5","journal-title":"Lancet"},{"issue":"1","key":"2074_CR32","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s10194-022-01510-z","volume":"23","author":"AK Eigenbrodt","year":"2022","unstructured":"Eigenbrodt AK, Christensen RH, Ashina H, Iljazi A, Christensen CE, Steiner TJ et al (2022) Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency. J Headache Pain 23(1):140. https:\/\/doi.org\/10.1186\/s10194-022-01510-z","journal-title":"J Headache Pain"},{"issue":"10268","key":"2074_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM et al (2021) Oral Rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet 397(10268):51\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(20)32544-7","journal-title":"Lancet"},{"issue":"8","key":"2074_CR34","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L et al (2021) Atogepant for the preventive treatment of migraine. N Engl J Med 385(8):695\u2013706. https:\/\/doi.org\/10.1056\/NEJMoa2035908","journal-title":"N Engl J Med"},{"issue":"10404","key":"2074_CR35","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S0140-6736(23)01049-8","volume":"402","author":"P Pozo-Rosich","year":"2023","unstructured":"Pozo-Rosich P, Ailani J, Ashina M, Goadsby PJ, Lipton RB, Reuter U et al (2023) Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 402(10404):775\u2013785. https:\/\/doi.org\/10.1016\/S0140-6736(23)01049-8","journal-title":"Lancet"},{"issue":"3","key":"2074_CR36","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40259-022-00530-0","volume":"36","author":"F Cohen","year":"2022","unstructured":"Cohen F, Yuan H, Silberstein SD (2022) Calcitonin Gene-Related peptide (CGRP)-Targeted monoclonal antibodies and antagonists in migraine: current evidence and rationale. BioDrugs 36(3):341\u2013358. https:\/\/doi.org\/10.1007\/s40259-022-00530-0","journal-title":"BioDrugs"},{"issue":"8","key":"2074_CR37","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1111\/head.13930","volume":"60","author":"G Berman","year":"2020","unstructured":"Berman G, Croop R, Kudrow D, Halverson P, Lovegren M, Thiry AC et al (2020) Safety of Rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine. Headache 60(8):1734\u20131742. https:\/\/doi.org\/10.1111\/head.13930","journal-title":"Headache"},{"issue":"3","key":"2074_CR38","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/WCO.0000000000000925","volume":"34","author":"MW Green","year":"2021","unstructured":"Green MW (2021) Medication overuse headache. Curr Opin Neurol 34(3):378\u2013383. https:\/\/doi.org\/10.1097\/WCO.0000000000000925","journal-title":"Curr Opin Neurol"},{"issue":"9","key":"2074_CR39","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1177\/0333102420938652","volume":"40","author":"E Navratilova","year":"2020","unstructured":"Navratilova E, Behravesh S, Oyarzo J, Dodick DW, Banerjee P, Porreca F (2020) Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. Cephalalgia 40(9):892\u2013902. https:\/\/doi.org\/10.1177\/0333102420938652","journal-title":"Cephalalgia"},{"issue":"7","key":"2074_CR40","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/head.14775","volume":"64","author":"RB Lipton","year":"2024","unstructured":"Lipton RB, Ailani J, Mullin K, Pavlovic JM, Tepper SJ, Dodick DW et al (2024) Situational prevention: pharmacotherapy during periods of increased risk for migraine attacks. Headache 64(7):859\u2013864. https:\/\/doi.org\/10.1111\/head.14775","journal-title":"Headache"},{"issue":"8","key":"2074_CR41","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/head.14619","volume":"63","author":"EA MacGregor","year":"2023","unstructured":"MacGregor EA, Hutchinson S, Lai H, Dabruzzo B, Yu SY, Trugman JM et al (2023) Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis. Headache 63(8):1135\u20131144. https:\/\/doi.org\/10.1111\/head.14619","journal-title":"Headache"},{"key":"2074_CR42","doi-asserted-by":"publisher","first-page":"1431562","DOI":"10.3389\/fphar.2024.1431562","volume":"15","author":"Q Liang","year":"2024","unstructured":"Liang Q, Liao X, Wu H, Huang Y, Liang T, Li H (2024) Real-world study of adverse events associated with Gepant use in migraine treatment based on the vigiaccess and U.S. Food and drug administration\u2019s adverse event reporting system databases. Front Pharmacol 15:1431562. https:\/\/doi.org\/10.3389\/fphar.2024.1431562","journal-title":"Front Pharmacol"},{"issue":"8","key":"2074_CR43","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s11916-022-01064-4","volume":"26","author":"J Robblee","year":"2022","unstructured":"Robblee J, Harvey LK (2022) Cardiovascular disease and migraine: are the new treatments safe?? Curr Pain Headache Rep 26(8):647\u2013655. https:\/\/doi.org\/10.1007\/s11916-022-01064-4","journal-title":"Curr Pain Headache Rep"},{"issue":"1","key":"2074_CR44","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s10194-022-01424-w","volume":"23","author":"AO Gerard","year":"2022","unstructured":"Gerard AO, Merino D, Van Obberghen EK, Rocher F, Destere A, Lanteri-Minet M et al (2022) Calcitonin gene-related peptide-targeting drugs and Raynaud\u2019s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database. J Headache Pain 23(1):53. https:\/\/doi.org\/10.1186\/s10194-022-01424-w","journal-title":"J Headache Pain"},{"issue":"1","key":"2074_CR45","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1038\/s41598-025-87421-w","volume":"15","author":"N Lee","year":"2025","unstructured":"Lee N, Ok JH, Rhee SJ, Kim Y (2025) Disproportionality analysis of Raynaud\u2019s phenomenon associated with calcitonin gene-related peptide inhibitors using the food and drug administration adverse event reporting system. Sci Rep 15(1):5675. https:\/\/doi.org\/10.1038\/s41598-025-87421-w","journal-title":"Sci Rep"},{"issue":"9","key":"2074_CR46","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/03331024211000311","volume":"41","author":"S Hutchinson","year":"2021","unstructured":"Hutchinson S, Silberstein SD, Blumenfeld AM, Lipton RB, Lu K, Yu SY et al (2021) Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II. Cephalalgia 41(9):979\u2013990. https:\/\/doi.org\/10.1177\/03331024211000311","journal-title":"Cephalalgia"},{"issue":"5","key":"2074_CR47","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s40122-024-00626-1","volume":"13","author":"D True","year":"2024","unstructured":"True D, Mullin K, Croop R (2024) Safety of Rimegepant in adults with migraine and cardiovascular risk factors: analysis of a multicenter, Long-Term, Open-Label study. Pain Ther 13(5):1203\u20131218. https:\/\/doi.org\/10.1007\/s40122-024-00626-1","journal-title":"Pain Ther"},{"key":"2074_CR48","doi-asserted-by":"publisher","unstructured":"Best P, Harriott A, Monteith T, Tassorelli C, Nahas S, Davidovic G et al (2023) Post hoc analysis of progress: evaluating the safety of Atogepant in participants with chronic migraine and cardiovascular risk factors. J Neurol Sci 455. https:\/\/doi.org\/10.1016\/j.jns.2023.121631","DOI":"10.1016\/j.jns.2023.121631"},{"issue":"6","key":"2074_CR49","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/head.14135","volume":"61","author":"S Joshi","year":"2021","unstructured":"Joshi S, Tepper SJ, Lucas S, Rasmussen S, Nelson R (2021) A narrative review of the importance of pharmacokinetics and drug-drug interactions of preventive therapies in migraine management. Headache 61(6):838\u2013853. https:\/\/doi.org\/10.1111\/head.14135","journal-title":"Headache"},{"issue":"9","key":"2074_CR50","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1007\/s10072-022-06184-8","volume":"43","author":"C Altamura","year":"2022","unstructured":"Altamura C, Brunelli N, Marcosano M, Fofi L, Vernieri F (2022) Gepants - a long way to cure: a narrative review. Neurol Sci 43(9):5697\u20135708. https:\/\/doi.org\/10.1007\/s10072-022-06184-8","journal-title":"Neurol Sci"},{"key":"2074_CR51","doi-asserted-by":"publisher","unstructured":"Headaches in Pregnancy and Postpartum: ACOG Clinical Practice Guideline No. 3 (2022) Obstet Gynecol 139(5), 944\u2013972. https:\/\/doi.org\/10.1097\/AOG.0000000000004766","DOI":"10.1097\/AOG.0000000000004766"},{"key":"2074_CR52","doi-asserted-by":"publisher","unstructured":"Tourlas K, Pavitt S (2023) Safety and efficacy of oral calcitonin Gene-Related peptide receptor antagonists for the acute treatment of migraine in the pediatric population (P9-12.010). 2507 Neurology.100(17_supplement_2). https:\/\/doi.org\/10.1212\/WNL.0000000000202606","DOI":"10.1212\/WNL.0000000000202606"},{"key":"2074_CR53","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.pediatrneurol.2024.05.013","volume":"157","author":"L Moore","year":"2024","unstructured":"Moore L, Pakalnis A (2024) Calcitonin Gene-Related peptide inhibitors in the treatment of migraine in the pediatric and adolescent populations: A review. Pediatr Neurol 157:87\u201395. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2024.05.013","journal-title":"Pediatr Neurol"},{"issue":"9","key":"2074_CR54","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11910-024-01361-y","volume":"24","author":"MA Hird","year":"2024","unstructured":"Hird MA, Sandoe CH (2024) Migraine management in medically complex patients: a narrative review. Curr Neurol Neurosci Rep 24(9):423\u2013438. https:\/\/doi.org\/10.1007\/s11910-024-01361-y","journal-title":"Curr Neurol Neurosci Rep"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02074-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02074-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02074-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T13:33:07Z","timestamp":1748871187000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-025-02074-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2074"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02074-4","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PA has received speaker and advisory board honoraria from BL HUA, DKSH, Lundbeck, Pfizer, and ZP therapeutics. WR declares receiving speaker and advisory board honoraria from BL HUA, DKSH, Lundbeck, Pfizer, Viatris and ZP therapeutics. KV discloses participation in speaker\u2019s bureaus for Abbott, AbbVie, Daiichi Sankyo, DKSH, Eli Lilly, GSK, Lundbeck, Merck, Novartis, Pfizer, Servier, Teva Pharma, Viatris, ZP therapeutics and Zuellig Pharma, as well as being a consultant for Daiichi Sankyo, Lundbeck, Novartis, Pfizer, Teva Pharma, and Zuellig Pharma. TP (Thanakit Pongpitakmetha) has received speaker honoraria from BL HUA, Daiichi Sankyo, Eisai, Lundbeck, Pfizer, Servier and ZP therapeutics. ST (Sekh Thanprasertsuk) reports speaker and advisory board honoraria from BL HUA, DKSH, Lundbeck, Pfizer, Viatris and ZP therapeutics. TP (Thaninjitra Poonpedpun) declares receiving speaker and advisory board honoraria from DKSH, Lundbeck, Pfizer and ZP therapeutics. PS has received speaker honoraria from BL HUA, DKSH, Pfizer and ZP therapeutics. KS discloses potential interests in receiving speaker honoraria from DKSH, Pfizer and ZP therapeutics. KK has received speaker and advisory board honoraria from BL HUA, DKSH, Lundbeck, Pfizer, Viatris and ZP therapeutics. SK declares receiving honoraria as a speaker for BL HUA, DKSH, Lundbeck, Pfizer, Viatris and ZP therapeutics, as well as participation in advisory board meeting of Lundbeck. Both PD and CT report receiving an advisory board honorarium from Pfizer. NS has received speaker and advisory board honoraria from Abbott, A.Menarini, Bayer, BL HUA, Daiichi Sankyo, DKSH, Lundbeck, Novartis, Orion, Pfizer, Viatris and ZP therapeutics. NY received speaker and advisory board honoraria from BL HUA, Pfizer and ZP therapeutics. ST (Surat Tanprawate) discloses receiving speaker and advisory board honoraria from BL HUA, DKSH, Lundbeck, Pfizer, Viatris and ZP therapeutics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"131"}}